(MCK) McKesson - Ratings and Ratios

McKesson Corporation (NYSE:MCK) is a global healthcare services and distribution company operating through four core segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment is a leading distributor of branded, generic, specialty, biosimilar, and over-the-counter drugs, serving retail pharmacies, hospitals, and specialty practices. It also provides technology and clinical support solutions for oncology and specialty clinics, as well as operational and financial tools for pharmacies. The RxTS segment focuses on improving medication access and affordability by connecting patients, providers, payers, and biopharma companies. It offers solutions for prescription price transparency, benefit insights, and third-party logistics. The Medical-Surgical Solutions segment supplies medical products and equipment to healthcare providers, including physician offices, surgery centers, and home health agencies. Internationally, the company operates in Europe and Canada, serving wholesale, institutional, and retail customers. McKesson, founded in 1833, is headquartered in Irving, Texas, and is one of the largest healthcare distributors in the world.

Over the next three months, McKessons stock (NYSE:MCK) is expected to trade within a range influenced by its technical and fundamental trends. Based on the technical data, the stock is currently trading above its SMA20 (677.82) and SMA50 (647.49), indicating short-term bullish momentum. However, the SMA200 (583.44) remains below the current price, suggesting longer-term strength. The ATR of 18.10 indicates moderate volatility, with potential price swings of 3-5% in either direction. The stock has multiple support levels (661.0, 626.1, 607.0) that could act as floors if downward pressure emerges. On the fundamental side, McKessons high P/E ratio (31.65) compared to its forward P/E (18.52) suggests expectations of future earnings growth. The companys RoE of 51.23% reflects strong profitability, but the P/S ratio of 0.25 indicates undervaluation relative to its revenue. Overall, McKesson is likely to experience continued upward momentum, with potential resistance near its recent highs and support at 661.0 and 626.1.